You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

CLINICAL TRIALS PROFILE FOR METVIXIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for METVIXIA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02392390 ↗ Effects of Topical Dynamic Phototherapy on the Microbiota of Chronic Wounds Completed Centre Hospitalier Universitaire de Nīmes N/A 2015-10-01 The main objective of this study is to estimate the change in the relative numbers of commensal or low virulence potential bacteria before and after one session TDP.
NCT02511145 ↗ Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration Completed Galderma R&D Phase 1 2014-02-01 Exploratory, mono-center, randomized, intra-individual, controlled trial involving healthy volunteers to compare the effect on MAL penetration into the skin following various mechanical penetration enhancement techniques.
NCT02799069 ↗ Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy Completed Accovion GmbH Phase 3 2008-04-01 The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.
NCT02799069 ↗ Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy Completed Biofrontera Bioscience GmbH Phase 3 2008-04-01 The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.
NCT05104099 ↗ Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia Not yet recruiting Institut de Cancérologie de Lorraine Phase 2 2021-11-01 This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for METVIXIA

Condition Name

Condition Name for METVIXIA
Intervention Trials
Actinic Keratosis 1
Differentiated Vulvar Intraepithelial Neoplasia 1
Healthy 1
Leg Ulcer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for METVIXIA
Intervention Trials
Neoplasms 1
Carcinoma, Squamous Cell 1
Carcinoma in Situ 1
Keratosis, Actinic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for METVIXIA

Trials by Country

Trials by Country for METVIXIA
Location Trials
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for METVIXIA

Clinical Trial Phase

Clinical Trial Phase for METVIXIA
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for METVIXIA
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for METVIXIA

Sponsor Name

Sponsor Name for METVIXIA
Sponsor Trials
Biofrontera Bioscience GmbH 1
Institut de Cancérologie de Lorraine 1
Centre Hospitalier Universitaire de Nīmes 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for METVIXIA
Sponsor Trials
Industry 3
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.